

In the immunohistochemistry, there were several inflammatory pseudotumor cases with various types of GLUT-1 immunoreactivity, but it was difficult to have a quantitative comparison with malignant tumor cases. In this article, we eliminated some inflammatory pseudotumor cases. Further study is needed.

CONCLUSION

In pancreatic FDG PET imaging, a high degree of both GLUT-1 expression and tumor cell cellularity is needed for a pancreatic tumor to have a higher FDG accumulation. GLUT-1 expression was supposed to play an essential role in higher FDG accumulation. Only in the condition of GLUT-1 strong positive expression was the cellularity supposed to have a significant effect on SUVs.

ACKNOWLEDGMENTS

We thank Dr. Yasuhiro Magata, Dr. Satoshi Sasayama and Haruhiro Kitano of the Department of Nuclear Medicine, Kyoto University Faculty of Medicine, for technical assistance with PET imaging.

REFERENCES

1. Bares R, Klever P, Hauptmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. *Radiology* 1994;192:79–86.
2. Hawkins RA, Hoh C, Dahlbom M, et al. PET cancer evaluations with FDG [Editorial]. *J Nucl Med* 1991;32:1555–1558.
3. Ishizu K, Sadato N, Yonekura Y, et al. Enhanced detection of brain tumors by [18F]fluorodeoxyglucose PET with glucose loading. *J Comput Assist Tomogr* 1994;18:12–15.
4. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. *J Nucl Med* 1988;29:181–186.
5. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. *J Nucl Med* 1990;31:1927–1932.
6. Strauss LG, Clorius JH, Schlag P, et al. Recurrence of colorectal tumors: PET evaluation. *Radiology* 1989;170:329–332.
7. Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. *J Nucl Med* 1994;35:1965–1969.
8. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. *Radiology* 1991;179:765–770.
9. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. *Radiology* 1995;195:345–352.
10. Inokuma T, Tamaki N, Torizuka T, et al. Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. *J Nucl Med* 1995;36:229–235.
11. Yonekura Y, Benua RS, Brill AB, et al. Increased accumulation of 2-deoxy-2-[18F]fluoro-D-glucose in liver metastases from colon carcinoma. *J Nucl Med* 1982;23:1133–1137.
12. Warburg O. The metabolism of tumors. *Constable* 1930:254–270.
13. Higashi T, Tamaki N, Honda T, et al. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. *J Nucl Med* 1997;38:1337–1344.
14. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. *J Nucl Med* 1993;34:414–419.
15. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. *J Nucl Med* 1995;36:1811–1817.
16. Wahl RL. Targeting glucose transporters for tumor imaging: “sweet” idea, “sour” results. *J Nucl Med* 1996;37:1038–1041.
17. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL. Are inflammatory cells important? *J Nucl Med* 1995;36:1854–1861.
18. Kubota K, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. *J Nucl Med* 1992;33:1972–1980.
19. Ito K, Kato T, Ohta M, et al. Diagnostic usefulness and limitation of FDG-PET in recurrent rectal cancer. In: Matsuzawa T, ed. *Proceedings of the second international symposium of clinical PET in oncology*. Singapore: World Scientific; 1994:199–206.
20. Kato T, Fukatsu H, Ito K, et al. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: unsolved problem. *Eur J Nucl Med* 1995;22:32–39.
21. Tamaki N, Yonekura Y, Yamashita K, et al. Relation of left ventricular perfusion and wall motion with metabolic activity in persistent defects on thallium-201 tomography healed myocardial infarction. *Am J Cardiol* 1988;62:202–208.
22. Woodard HQ, Bigler RE, Freed B. Expression of tissue isotope distribution [Letter]. *J Nucl Med* 1975;16:958–959.
23. Wang LD, Shi ST, Zhou Q, et al. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. *Int J Cancer* 1994;59:514–519.
24. Cooley WW, Lohnes PR. *Multivariate data analysis*. New York: John Wiley and Sons; 1971.
25. Wang ZH, Manabe T, Ohshio G, et al. Immunohistochemical study of heparan sulfate proteoglycan in adenocarcinomas of the pancreas. *Pancreas* 1994;9:758–763.
26. Ohshio G, Yoshioka H, Manabe T, et al. Expression of sialosyl-Tn antigen (monoclonal antibody MLS102 reactive) in normal tissues and malignant tumors of the digestive tract. *J Cancer Res Clin Oncol* 1994;120:325–330.
27. Okazumi S, Enomoto K, Fukunaga T, et al. Evaluation of pancreatic lesions using 18F-fluorodeoxyglucose PET. *J Japan Pancreas Society* 1994;9:155–160.
28. Porter MR and Frantz VK. Tumors associated with hypoglycemia: pancreatic and extrapancreatic. *Am J Med* 1956;21:944.
29. Merrill NW, Plevin R, Gould GW. Growth factors, mitogens, oncogenes and the regulation of glucose transport. *Cell Signal* 1993;5:667–675.
30. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases glucose transporter gene transcription. *Science* 1987;235:1495–1498.
31. Dermietzel R, Krause D, Kremer M, Wang C, Stevenson B. Pattern of glucose transporter (Glut 1) expression in embryonic brains is related to maturation of blood-brain barrier tightness. *Dev Dyn* 1992;193:152–163.
32. Hermanek P, Sobin LH. *TNM classification of malignant tumors*, 4th ed. New York: Springer-Verlag; 1987.

Request for New Data: *MIRD Radionuclide Data and Decay Schemes*, second edition

During 1999, the SNM Department of Communications is planning to publish a new edition of *MIRD Radionuclide Data and Decay Schemes*. David A. Weber, PhD, and coauthors intend to update all radionuclide data and decay schemes with the latest peer-reviewed tabulations. They also will include new radionuclides that have become relevant to the nuclear medicine community or were overlooked in the current edition. In view of the substantial revision to this valuable nuclear medicine reference work, the authors are requesting suggestions or recommendations for additional radionuclides, tabular data or other information to appear in the new edition. Suggestions and recommendations may be sent to David A. Weber, PhD, Radiology Research FOLB II-E, 2421 45th St., University of California—Davis Medical Center, Sacramento, CA 95817-6364 (e-mail: daweber@ucdavis.edu).